Abstract Background and Objective Managed entry agreements (MEAs) consist of a set of
instruments to reduce the uncertainty and the budget impact of new high-priced medicines; …

Background The number of market approvals of orphan medicinal products (OMPs) has
been increasing steadily in the last 3 decades. While OMPs can offer a unique chance for …

With the escalating incidence and mortality rates of lung cancer, the targeted drugs
assessment has emerged a key problem, serving as the foundation for incorporating …

Background Patient access to orphan medicinal products (OMPs) is limited and varies
between countries, reimbursement decisions on OMPs are complex, and there is a need for …

Rare diseases are associated with difficulties in addressing unmet medical needs, lack of
access to treatment, high prices, evidentiary mismatch, equity, etc. While challenges facing …

Supply chain digitalisation equipment's raise concerns for hospital decision-makers,
especially regarding the cost-efficiency ratio, usually evaluated through health technologies …

Objective: The affordability of rare disease drugs has become a social issue that cannot be
ignored. This study aims to evaluate the current price and affordability of rare disease drugs …

Abstract Background and Objectives There are significant challenges when obtaining
clinical and economic evidence for health technology assessments of rare diseases. Many …

Objectives: This study aimed to understand Managed Entry Agreements (MEAs) in Korea
through the framework of three streams of the policy window model and its practical …

Background This study aimed to establish a suitable value assessment framework for
orphan medicinal products in China based on the multi-criteria decision analysis (MCDA) …